reports
An unfavourable environment weighs on CORBUS PHARMS.HOLDINGS, which se...
The independent financial analyst theScreener just requalified the general evaluation of CORBUS PHARMS.HOLDINGS (US), active in the Biotechnology industry. As regards its fundamental valuation, the title still shows 1 out of 4 stars and its market behaviour is seen as risky. theScreener believes that the unfavourable environment weighs on the sector and penalises the company, which sees a downgrade to its general evaluation to Negative. As of the analysis date November 30, 2021, the closing pric...
Corbus Pharmaceuticals Reports Second Quarter 2021 Financial Results a...
Corbus Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Updates Company focused on gaining regulatory clarity for late-stage lenabasum program and advancing programs targeting the endocannabinoid system and integrins into the clinicAugmenting the pipeline through business development continues to be a priorityCash and investments on hand of $114M provides projected runway into first quarter of 2024 Norwood, MA, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), an immunology company...
Corbus Pharmaceuticals Announces Topline Results from DETERMINE Phase ...
Corbus Pharmaceuticals Announces Topline Results from DETERMINE Phase 3 Study of Lenabasum for Treatment of Dermatomyositis Study did not meet primary endpoint of Total Improvement Score (TIS) at Week 28Additional findings included nominally significant improvements in TIS (p = 0.0302) and CDASI (p = 0.0166) depending on the dermatomyositis subtypeLenabasum treatment was safe and well-tolerated in this study Norwood, MA, June 24, 2021 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), an immunology company developing innovative medicin...
Corbus Pharmaceuticals Licenses Two Integrin Targeting mAbs Further Ex...
Corbus Pharmaceuticals Licenses Two Integrin Targeting mAbs Further Expanding Pipeline into Cancer and Fibrotic Diseases Corbus diversifies pipeline with two new mAbs that target integrins that inhibit activation of TGFβ High potency anti-αvβ8 mAb licensed from University of California San Francisco and anti-αvβ6/αvβ8 mAb licensed from Panorama Research Inc. Both mAbs expected to start Phase 1 testing in 2022Capital and resources in place to advance multiple programs into clinical developmentCompany to host conference call and webcast today, Tuesday, June 1, 2021 at 8:30 a.m. ET Norwoo...
Corbus Pharmaceuticals Announces Publication of Two Abstracts at EULAR...
Corbus Pharmaceuticals Announces Publication of Two Abstracts at EULAR 2021 Virtual Congress Norwood, MA, May 25, 2021 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced the publication of two abstracts at the European League Against Rheumatism (EULAR) 2021 Virtual Congress that will be taking place June 2-5, 2021. Details of the presentations are as follows: Presentation Title: Phase 3 Trial of Lenab...
CORBUS PHARMACEUTICALS ANNOUNCES ADJOURNMENT OF ANNUAL MEETING
CORBUS PHARMACEUTICALS ANNOUNCES ADJOURNMENT OF ANNUAL MEETING Norwood, MA, May 19, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced that it has adjourned its 2021 Annual Meeting of Stockholders (the “Annual Meeting”) in order to provide stockholders additional time within which to vote on all proposals, including Proposal 4 to approve an amendment to the Company’s certificate of incorporation to increase the Company’s authorized shares...
Corbus Pharmaceuticals Reports First Quarter 2021 Financial Results an...
Corbus Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Updates Phase 3 study of lenabasum in dermatomyositis on schedule for topline data in Q2 2021 Company focused on advancing cannabinoid programs in metabolic diseases and cancer into the clinic in 2022Corbus is actively engaging with potential partners to expand its pipeline through acquisition of external assetsCash and investments on hand of $125M provides projected runway into Q1 2024 Norwood, MA, May 13, 2021 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Co...
Corbus Pharmaceuticals to Present at Three Upcoming Investor Conferenc...
Corbus Pharmaceuticals to Present at Three Upcoming Investor Conferences Norwood, MA, May 11, 2021 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will be presenting at three upcoming virtual investor conferences. The following are the details for the conferences: 2021 RBC Capital Markets Global Healthcare Conference Event:...
Corbus Pharmaceuticals Announces Completion of Enrollment in NIH-Spons...
Corbus Pharmaceuticals Announces Completion of Enrollment in NIH-Sponsored Phase 2 Study of Lenabasum for Treatment of Systemic Lupus Erythematosus (SLE) First study to explore potential benefit of a cannabinoid receptor type 2 agonist in SLEStudy sponsored and funded by the Nastional Institute of Allergy and Infectious Diseases through the Autoimmunity Centers of Excellence (ACE) Cooperative NetworkTopline data expected in the second half of 2021SLE is a serious autoimmune disease with multi-organ involvement and affects more than 200,000 Americans Norwood, MA, April 20, 2021 (GLOBE N...
Corbus Pharmaceuticals Reports Last Subject Visit in DETERMINE Phase 3...
Corbus Pharmaceuticals Reports Last Subject Visit in DETERMINE Phase 3 Study of Lenabasum for Treatment of Dermatomyositis Topline data on schedule for Q2 2021Dermatomyositis is a rare and life-threatening autoimmune disease characterized by skin and muscle inflammation, and affects ~80,000 people in North America, EU, and JapanThere is a significant need for safer and more effective treatments in dermatomyositis because of limitations of current treatment options Norwood, MA, March 30, 2021 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or t...
Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2020 Financ...
Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2020 Financial Results ●Phase 3 study of lenabasum in dermatomyositis on schedule for topline data in Q2 2021 ●Company focused on advancing in-house programs in metabolic diseases, fibrotic disorders, and cancer with clinical studies projected for 2022 ●Corbus is actively engaging with potential partners to expand its pipeline through acquisition of external assets ●Cash on hand of $127M, projected runway into 2024 ●Company to host conference call and webcast today, Monday, March 15th at 8:30 a.m. ET Norwood, MA, March 15, ...
Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences
Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences Norwood, MA, March 09, 2021 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will be presenting at two upcoming virtual investor conferences. The following are the details for the conferences: 33rd Annual Virtual Roth Conference Event: Fireside Chat Discussi...
Corbus Pharmaceuticals to Report Fourth Quarter and Year-End 2020 Resu...
Corbus Pharmaceuticals to Report Fourth Quarter and Year-End 2020 Results on March 15, 2021 • Company to host conference call and webcast on Monday, March 15, 2021 at 8:30 a.m. ET Norwood, MA, March 08, 2021 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced that it will report its fourth quarter and year-end financial results on Monday, March 15th. Corbus management will host a conference call and liv...
Corbus Pharmaceuticals Announces Presentations at the New York Academy...
Corbus Pharmaceuticals Announces Presentations at the New York Academy of Sciences Webinar on Targeting the Endocannabinoid System to Treat Human Diseases Presentations about compounds in Corbus’ pipeline will highlight mechanistic studies of lenabasum, a CB2 agonist, and preclinical data from CB2 agonist oncology program and CB1 inverse agonist metabolism program Norwood, MA, Jan. 20, 2021 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medicines that target the endo...
Corbus Pharmaceuticals to Present at the Jefferies Virtual London Heal...
Corbus Pharmaceuticals to Present at the Jefferies Virtual London Healthcare Conference Fireside chat with live audio webcast on Thursday, November 19th at 12:35 PM EST Norwood, MA, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in a fireside chat at the Jefferies Virtual London Healthcare Conference on Thursday,...
Corbus Pharmaceuticals Reports Third Quarter Financial Results and Pro...
Corbus Pharmaceuticals Reports Third Quarter Financial Results and Provides Corporate Updates Company intends to shorten fully-enrolled Phase 3 dermatomyositis trial to 28 weeks from 52 weeks following recent developments in competitive landscape; data now expected as early as the second quarter of 2021Expected cash runway extended into second quarter of 2022 as a result of Company restructuring, with potential to extend cash runway even further due to shortening Phase 3 dermatomyositis trialCompany will also focus on progressing pipeline compounds toward clinical testing Reported topline d...
Corbus Pharmaceuticals Presents Additional Data from RESOLVE-1 Study i...
Corbus Pharmaceuticals Presents Additional Data from RESOLVE-1 Study in Systemic Sclerosis Topline data remain as previously reportedPost-hoc analyses showed lenabasum treatment was associated with a benefit in lung function (forced vital capacity) in subjects on established background immunosuppressant therapies (greater than 2 years)Focusing on forced vital capacity in patients on established immunosuppressant therapies could address a key unmet need and represents a potential commercial opportunitySystemic sclerosis is a rare, life-threatening autoimmune disease affecting up to 75K Ameri...
Corbus Pharmaceuticals to Report Third Quarter Results on November 10,...
Corbus Pharmaceuticals to Report Third Quarter Results on November 10, 2020 Company to host conference call and webcast on Tuesday, November 10 at 8:30 a.m. ET Norwood, MA, Nov. 03, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced that it will report its third quarter financial results on Tuesday, November 10. Corbus management will host a conference call and live audio webcast to discuss the op...
Corbus Pharmaceuticals Announces Presentation of Data from its Phase 2...
Corbus Pharmaceuticals Announces Presentation of Data from its Phase 2b Study in Cystic Fibrosis at NACFC 2020 As previously reported, lenabasum did not meet its primary efficacy endpoint in the studyLenabasum was well tolerated with no new safety findingsExploratory post-hoc analyses revealed unexpectedly low pulmonary exacerbation (PEx) rates in subjects from five eastern European countries (21% of total subjects) who received placebo; PEx rates in these subjects were 85% lower than in subjects from other countriesPost-hoc analyses in subjects with similar FEV1% predicted at baseline and ...
Corbus Pharmaceuticals Announces Three Lenabasum Abstracts to be Prese...
Corbus Pharmaceuticals Announces Three Lenabasum Abstracts to be Presented at ACR Convergence 2020 Preliminary baseline subject demographics and disease characteristics in a Phase 3 clinical trial of the safety and efficacy of lenabasum in dermatomyositis (DETERMINE)Cannabinoid receptor type 2 expression is increased in lesional dermatomyositis skin compared to healthy skin and lenabasum significantly reduces CD8+ T cell expression of interferon γOf the four systemic sclerosis subjects who developed COVID-19 infection while taking lenabasum during SSc OLE, only one subject required limited ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.